NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/24/2023
Back to search
Official data from USPTO
B BRENUS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/24/2023
Trademark type
Combined
Nice classes
5
Filing date
08/25/2020
Registration date
11/23/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/23/2021
Last transaction
11/23/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
34
Owner location
FR
Examiner
BROWNE, LUCY
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the black stylized wording "BRENUS" centered above the black stylized wording "PHARMA" with a short black line extending outward from each side of the wording "PHARMA", all of which is below a design of a light blue letter "B" that is surrounded by two light blue inverted triangles superimposed over one another with one appearing larger than the other. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
Holders and representatives
Holders
B. P. (pessoa física)
Representatives
Adam Weiss PatShegen IP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for treating pathologies that are controllable or curable by stimulated immunological reaction from a patientthrough infectious or oncological diseases; Veterinary productsveterinary preparations for treating pathologies that are controllable or curable by stimulated immunological reaction from an animalthrough infectious or oncological diseases; Chemical preparations for pharmaceutical purposesfor treating pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Biological preparations for medical or therapeutic purposespreparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Biological preparations for veterinary purposespreparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Pharmaceutical preparationsimmune system aids for use in human medicine; Diagnostic preparations for medical use; Diagnostic preparations for veterinary use; Immunostimulants under the pharmaceutical monopoly; medicines in the nature of vaccinal administrations for stimulating the immune system for use in human medicine; Serums under the pharmaceutical monopoly for medical purposespharmaceutical serums for the treatment of the immune system; Biocellular preparations for therapeutic or medical purposespharmaceutical preparations for the treatment of the immune system
Publications
History of USPTO decisions and trademark events.
29 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/06/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/12/2022
FIMP
FINAL DISPOSITION PROCESSED
05/11/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/23/2021
GPNX
NOTIFICATION PROCESSED BY IB
09/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2021
PUBO
PUBLISHED FOR OPPOSITION
09/07/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/23/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/18/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/18/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/03/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/03/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/03/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/03/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/04/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/04/2021
RFNT
REFUSAL PROCESSED BY IB
01/30/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/09/2021
RFRR
REFUSAL PROCESSED BY MPU
01/09/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/24/2020
CNRT
NON-FINAL ACTION WRITTEN
12/23/2020
DOCK
ASSIGNED TO EXAMINER
12/23/2020
MAFR
APPLICATION FILING RECEIPT MAILED
11/03/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/30/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/29/2020
Continuous trademark protection
Get notified about every new filing that threatens B BRENUS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.